Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial

Philip Mw Bath; Jason P Appleton; Maia Beridze; Hanne Christensen; Robert A Dineen; Lelia Duley; Timothy J England; Stan Heptinstall; Marilyn James; Kailash Krishnan; Hugh S Markus; Stuart Pocock; Annemarei Ranta; Thompson G Robinson; Katie Flaherty; Polly Scutt; Graham S Venables; Lisa J Woodhouse; Nikola Sprigg

doi:10.1177/1747493016677988

Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial

Philip Mw Bath, Jason P Appleton, Maia Beridze, Hanne Christensen, Robert A Dineen, Lelia Duley, Timothy J England, Stan Heptinstall, Marilyn James, Kailash Krishnan, Hugh S Markus, Stuart Pocock, Annemarei Ranta, Thompson G Robinson, Katie Flaherty, Polly Scutt, Graham S Venables, Lisa J Woodhouse, Nikola Sprigg

Institut for Klinisk Medicin

3 Citationer (Scopus)

54 Downloads (Pure)

Abstract

Background The risk of recurrence following ischemic stroke or transient ischemic attack is highest immediately after the event. Antiplatelet agents are effective in reducing the risk of recurrence and two agents are superior to one in the early phase after ictus. Design The triple antiplatelets for reducing dependency after ischemic stroke trial was an international multicenter prospective randomized open-label blinded-endpoint trial that assessed the safety and efficacy of short-term intensive antiplatelet therapy with three agents (combined aspirin, clopidogrel and dipyridamole) as compared with guideline treatment in acute ischemic stroke or transient ischemic attack. The primary outcome was stroke recurrence and its severity, measured using the modified Rankin Scale at 90 days. Secondary outcomes included recurrent vascular events, functional measures (cognition, disability, mood, quality of life), and safety (bleeding, death, serious adverse events). Data are number (%) or mean (standard deviation, SD). Results Recruitment ran from April 2009 to March 2016; 3096 patients were recruited from 106 sites in four countries (Denmark 1.6%, Georgia 2.7%, New Zealand 0.2%, UK 95.4%). Randomization characteristics included: age 69.0 (10.1) years; male 1945 (62.8%); time onset to randomization 29.4 (11.9) h; stroke severity (National Institutes for Health Stroke Scale) 2.8 (3.6); blood pressure 143.5 (18.2)/79.5 (11.4) mmHg; IS 2143 (69.2%), transient ischemic attack 953 (30.8%). Conclusion Triple antiplatelets for reducing dependency after ischemic stroke was a large trial of intensive/triple antiplatelet therapy in acute ischemic stroke and transient ischemic attack, and included participants from four predominantly Caucasian countries who were representative of patients in many western stroke services.

Originalsprog	Engelsk
Tidsskrift	International Journal of Stroke
Vol/bind	12
Udgave nummer	5
Sider (fra-til)	524-538
Antal sider	15
ISSN	1747-4930
DOI	https://doi.org/10.1177/1747493016677988
Status	Udgivet - 1 jul. 2017

Adgang til dokumentet

10.1177/1747493016677988Licens: CC BY

1747493016677988Forlagets udgivne version, 4,89 MBLicens: CC BY

Citationsformater

Bath, P. M., Appleton, J. P., Beridze, M., Christensen, H., Dineen, R. A., Duley, L., England, T. J., Heptinstall, S., James, M., Krishnan, K., Markus, H. S., Pocock, S., Ranta, A., Robinson, T. G., Flaherty, K., Scutt, P., Venables, G. S., Woodhouse, L. J., & Sprigg, N. (2017). Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial. International Journal of Stroke, 12(5), 524-538. https://doi.org/10.1177/1747493016677988

Bath, PM, Appleton, JP, Beridze, M, Christensen, H, Dineen, RA, Duley, L, England, TJ, Heptinstall, S, James, M, Krishnan, K, Markus, HS, Pocock, S, Ranta, A, Robinson, TG, Flaherty, K, Scutt, P, Venables, GS, Woodhouse, LJ & Sprigg, N 2017, 'Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial', International Journal of Stroke, bind 12, nr. 5, s. 524-538. https://doi.org/10.1177/1747493016677988

@article{cf844b149aee46479c4d4d61447b06f6,

title = "Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial",

abstract = "Background The risk of recurrence following ischemic stroke or transient ischemic attack is highest immediately after the event. Antiplatelet agents are effective in reducing the risk of recurrence and two agents are superior to one in the early phase after ictus. Design The triple antiplatelets for reducing dependency after ischemic stroke trial was an international multicenter prospective randomized open-label blinded-endpoint trial that assessed the safety and efficacy of short-term intensive antiplatelet therapy with three agents (combined aspirin, clopidogrel and dipyridamole) as compared with guideline treatment in acute ischemic stroke or transient ischemic attack. The primary outcome was stroke recurrence and its severity, measured using the modified Rankin Scale at 90 days. Secondary outcomes included recurrent vascular events, functional measures (cognition, disability, mood, quality of life), and safety (bleeding, death, serious adverse events). Data are number (%) or mean (standard deviation, SD). Results Recruitment ran from April 2009 to March 2016; 3096 patients were recruited from 106 sites in four countries (Denmark 1.6%, Georgia 2.7%, New Zealand 0.2%, UK 95.4%). Randomization characteristics included: age 69.0 (10.1) years; male 1945 (62.8%); time onset to randomization 29.4 (11.9) h; stroke severity (National Institutes for Health Stroke Scale) 2.8 (3.6); blood pressure 143.5 (18.2)/79.5 (11.4) mmHg; IS 2143 (69.2%), transient ischemic attack 953 (30.8%). Conclusion Triple antiplatelets for reducing dependency after ischemic stroke was a large trial of intensive/triple antiplatelet therapy in acute ischemic stroke and transient ischemic attack, and included participants from four predominantly Caucasian countries who were representative of patients in many western stroke services.",

keywords = "Aged, Aspirin/adverse effects, Brain Ischemia/drug therapy, Dipyridamole/adverse effects, Drug Therapy, Combination, Female, Humans, Male, Platelet Aggregation Inhibitors/adverse effects, Severity of Illness Index, Stroke/drug therapy, Ticlopidine/adverse effects, Treatment Outcome",

author = "Bath, {Philip Mw} and Appleton, {Jason P} and Maia Beridze and Hanne Christensen and Dineen, {Robert A} and Lelia Duley and England, {Timothy J} and Stan Heptinstall and Marilyn James and Kailash Krishnan and Markus, {Hugh S} and Stuart Pocock and Annemarei Ranta and Robinson, {Thompson G} and Katie Flaherty and Polly Scutt and Venables, {Graham S} and Woodhouse, {Lisa J} and Nikola Sprigg",

year = "2017",

month = jul,

day = "1",

doi = "10.1177/1747493016677988",

language = "English",

volume = "12",

pages = "524--538",

journal = "International Journal of Stroke",

issn = "1747-4930",

publisher = "SAGE Publications",

number = "5",

}

TY - JOUR

T1 - Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial

AU - Bath, Philip Mw

AU - Appleton, Jason P

AU - Beridze, Maia

AU - Christensen, Hanne

AU - Dineen, Robert A

AU - Duley, Lelia

AU - England, Timothy J

AU - Heptinstall, Stan

AU - James, Marilyn

AU - Krishnan, Kailash

AU - Markus, Hugh S

AU - Pocock, Stuart

AU - Ranta, Annemarei

AU - Robinson, Thompson G

AU - Flaherty, Katie

AU - Scutt, Polly

AU - Venables, Graham S

AU - Woodhouse, Lisa J

AU - Sprigg, Nikola

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background The risk of recurrence following ischemic stroke or transient ischemic attack is highest immediately after the event. Antiplatelet agents are effective in reducing the risk of recurrence and two agents are superior to one in the early phase after ictus. Design The triple antiplatelets for reducing dependency after ischemic stroke trial was an international multicenter prospective randomized open-label blinded-endpoint trial that assessed the safety and efficacy of short-term intensive antiplatelet therapy with three agents (combined aspirin, clopidogrel and dipyridamole) as compared with guideline treatment in acute ischemic stroke or transient ischemic attack. The primary outcome was stroke recurrence and its severity, measured using the modified Rankin Scale at 90 days. Secondary outcomes included recurrent vascular events, functional measures (cognition, disability, mood, quality of life), and safety (bleeding, death, serious adverse events). Data are number (%) or mean (standard deviation, SD). Results Recruitment ran from April 2009 to March 2016; 3096 patients were recruited from 106 sites in four countries (Denmark 1.6%, Georgia 2.7%, New Zealand 0.2%, UK 95.4%). Randomization characteristics included: age 69.0 (10.1) years; male 1945 (62.8%); time onset to randomization 29.4 (11.9) h; stroke severity (National Institutes for Health Stroke Scale) 2.8 (3.6); blood pressure 143.5 (18.2)/79.5 (11.4) mmHg; IS 2143 (69.2%), transient ischemic attack 953 (30.8%). Conclusion Triple antiplatelets for reducing dependency after ischemic stroke was a large trial of intensive/triple antiplatelet therapy in acute ischemic stroke and transient ischemic attack, and included participants from four predominantly Caucasian countries who were representative of patients in many western stroke services.

AB - Background The risk of recurrence following ischemic stroke or transient ischemic attack is highest immediately after the event. Antiplatelet agents are effective in reducing the risk of recurrence and two agents are superior to one in the early phase after ictus. Design The triple antiplatelets for reducing dependency after ischemic stroke trial was an international multicenter prospective randomized open-label blinded-endpoint trial that assessed the safety and efficacy of short-term intensive antiplatelet therapy with three agents (combined aspirin, clopidogrel and dipyridamole) as compared with guideline treatment in acute ischemic stroke or transient ischemic attack. The primary outcome was stroke recurrence and its severity, measured using the modified Rankin Scale at 90 days. Secondary outcomes included recurrent vascular events, functional measures (cognition, disability, mood, quality of life), and safety (bleeding, death, serious adverse events). Data are number (%) or mean (standard deviation, SD). Results Recruitment ran from April 2009 to March 2016; 3096 patients were recruited from 106 sites in four countries (Denmark 1.6%, Georgia 2.7%, New Zealand 0.2%, UK 95.4%). Randomization characteristics included: age 69.0 (10.1) years; male 1945 (62.8%); time onset to randomization 29.4 (11.9) h; stroke severity (National Institutes for Health Stroke Scale) 2.8 (3.6); blood pressure 143.5 (18.2)/79.5 (11.4) mmHg; IS 2143 (69.2%), transient ischemic attack 953 (30.8%). Conclusion Triple antiplatelets for reducing dependency after ischemic stroke was a large trial of intensive/triple antiplatelet therapy in acute ischemic stroke and transient ischemic attack, and included participants from four predominantly Caucasian countries who were representative of patients in many western stroke services.

KW - Aged

KW - Aspirin/adverse effects

KW - Brain Ischemia/drug therapy

KW - Dipyridamole/adverse effects

KW - Drug Therapy, Combination

KW - Female

KW - Humans

KW - Male

KW - Platelet Aggregation Inhibitors/adverse effects

KW - Severity of Illness Index

KW - Stroke/drug therapy

KW - Ticlopidine/adverse effects

KW - Treatment Outcome

U2 - 10.1177/1747493016677988

DO - 10.1177/1747493016677988

M3 - Journal article

C2 - 27811309

SN - 1747-4930

VL - 12

SP - 524

EP - 538

JO - International Journal of Stroke

JF - International Journal of Stroke

IS - 5

ER -

Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater